Ios Ii Exam 1 Drugs Spring 2009

Front 1

amphetamine

Back 1

indirect sympathomimetic; non-polar

Front 2

metaraminol

Back 2

indirect/ direct sympathomimetic; alpha agonist

Front 3

methylphenidate

Back 3

indirect sympathomimetic

Front 4

ephedrine

Back 4

indirect/ direct sympathomimetic; alpha and beta agonist

Front 5

pseudoephedrine

Back 5

indirect/ direct sympathomimetic; alpha agonist

Front 6

phenylpropanolamine

Back 6

indirect/ direct sympathomimetic; a1, a2 agonist

Front 7

tyramine

Back 7

indirect sympathomimetic; no CNS action; MAO/COMT substrate

Front 8

isocarboxazid

Back 8

MAO-A and -B inhibitor

Front 9

phenelzine

Back 9

MAO-A and -B inhibitor

Front 10

tranylcypromine

Back 10

MAO-A and -B inhibitor

Front 11

clorgyline

Back 11

MAO-A inhibitor

Front 12

moclobemide

Back 12

MAO-A inhibitor; reversible

Front 13

selegiline

Back 13

MAO-B inhibitor

Front 14

rasagiline

Back 14

MAO-B inhibitor

Front 15

carbidopa

Back 15

blocks L-dopa into dopamine by blocking DOPA decarboxylase

Front 16

dopamine

Back 16

D1 ~ D2 > B1 >= a1 ~ a2 agonist: dopamine conc dependent; effects BV, kidney, heart; intermediate dose on heart = inc CO by inc­ contractility and dec afterload; improves renal perfusion

Front 17

a-methyldopa

Back 17

analogue of DOPA; competes w/ DOPA for DOPA decarboxylase; metabolizes into a-methyl-NE; decrease BP

Front 18

a-methyl-NE

Back 18

a2 agonist; false transmitter

Front 19

ibopamine

Back 19

D2 >= D1 > B2 >= B1 ~ a1 ~ a2 agonist: ibopamine conc dependent

Front 20

dopexamine

Back 20

D1, D2, B2 agonist

Front 21

fenoldopam

Back 21

D1; SELECTIVE; dec PVR leads to dec BP; ­inc natriuresis and diuresis leads to dec BP; used for Severe Malignant Hypertension

Front 22

bromocryptine

Back 22

D2 agonist (D1 partial agonist)

Front 23

pergolide

Back 23

D2 agonist (D1 partial antagonist)

Front 24

cabergoline

Back 24

D2 agonist, SELECTIVE

Front 25

ropinirole

Back 25

D2, D3 agonist

Front 26

pramipexole

Back 26

D2, D3 agonist

Front 27

guanethidine

Back 27

adrenergic nerone blocking drug (ANBD); inhibit CCA release; false transmitter; postjunctional supersensitivity

Front 28

bretylium

Back 28

adrenergic nerone blocking drug (ANBD); inhibit CCA release; false transmitter; postjunctional supersensitivity

Front 29

reserpine

Back 29

inhibits VMAT; dec CCA uptake into vesicles; dec symp func; vesicle destruction

Front 30

cocaine

Back 30

blocks re-uptake of CCA

Front 31

TCA's

Back 31

blocks re-uptake of CCA

Front 32

desipramine

Back 32

blocks re-uptake of CCA

Front 33

imipramine

Back 33

blocks re-uptake of CCA

Front 34

chlorpromozine

Back 34

blocks re-uptake of CCA

Front 35

entacapone

Back 35

blocks COMT peripherally so COMT can't metabolize L-dopa

Front 36

phenylephrine

Back 36

a1 agonist; reflexy bradycardia

Front 37

methoxamine

Back 37

a1 agonist; reflexy bradycardia

Front 38

phentolamine

Back 38

a1 and a2 antagonist

Front 39

prazosin

Back 39

a1 antagonist; a1 selective

Front 40

clonidine

Back 40

a2 agonist; dec BP; xerostomia, sedation, sudden discontinuation (HA, sweating, tachycardia, rebound HTN)

Front 41

apraclonidine

Back 41

a2 agonist; for open angle glaucoma

Front 42

guanfacine

Back 42

a2 agonist; dec BP

Front 43

guanabenz

Back 43

a2 agonist; dec BP

Front 44

yohimbine

Back 44

a2 antagonist; a2 selective

Front 45

NE

Back 45

a1, a2, B1, B3 agonist; net result ­inc BP and dec HR

Front 46

epinephrine

Back 46

a1, a2, B1, B2, B3 agonist; net result ­inc HR and slight inc­ BP

Front 47

isoproterenol

Back 47

beta1, 2, 3 agonist

Front 48

dobutamine

Back 48

beta1 > beta2 > alpha1 agonist depending on conc of dobutamine

Front 49

albuterol

Back 49

beta 2 agonist

Front 50

metaproterenol

Back 50

beta 2 agonist

Front 51

terbutaline

Back 51

beta 2 agonist

Front 52

ritodrine

Back 52

beta 2 agonist

Front 53

bitolterol

Back 53

beta 2 agonist; pro-drug

Front 54

pirbuterol

Back 54

beta 2 agonist

Front 55

propranolol

Back 55

beta 1 and beta 2 antagonist

Front 56

metoprolol

Back 56

beta 1 antagonist; B1 selective

Front 57

acebutolol

Back 57

B2 > B1; partial agonist (ISA) Intrinsic Sypathomimetic Activity

Front 58

carteolol

Back 58

B1, B2; partial agonist (ISA) Intrinsic Sypathomimetic Activity

Front 59

penbutolol

Back 59

B1, B2; partial agonist (ISA) Intrinsic Sypathomimetic Activity

Front 60

pindolol

Back 60

B1, B2; partial agonist (ISA) Intrinsic Sypathomimetic Activity

Front 61

a1 agonists properties

Back 61

excite smooth muscle, esp BV which inc afterload, contractile; EPI > NE

Front 62

a2 agonists properties

Back 62

inhibit NE release so dec BP, tone down symp activity so dec BP and inc vagal activity so dec HR; EPI > NE

Front 63

B1 agonists properties

Back 63

cardiac stimulation, renin secretion, relax smooth muscle; ISO > EPI ~ NE

Front 64

B2 agonists properties

Back 64

relax smooth muscle, esp airway, liver inc gluconeogenesis, SKM contractility; ISO > EPI > NE

Front 65

B3 agonist properties

Back 65

lipolysis, relaxes bladder; ISO ~ NE > EPI

Front 66

D1 agonists properties

Back 66

BV dilation, renal tubule vasodilation (diuresis), inc renin secretion (inc blood volume which is inconsistent w/ others); SE: flushing, HA

Front 67

D2 agonists properties

Back 67

inhibit NT release which can lead to dec PVR, dec BP, dec afterload (at low doses of dopamine); SE: N/V (CTZ)